clinical endpoints

Related by string. * clinicals . CLINICAL . Clinicals . Clinical : Phase III clinical trials . Phase III clinical . Phase 2b clinical . placebo controlled clinical trials . Clinical Excellence NICE / Endpoints . EndPoint . Endpoint : Secondary endpoints include . primary efficacy endpoint . secondary efficacy endpoints . video conferencing endpoints . Secondary endpoints included * *

Related by context. All words. (Click for frequent words.) 70 efficacy endpoints 70 secondary efficacy endpoints 69 efficacy endpoint 65 secondary endpoint 65 secondary efficacy endpoint 65 surrogate endpoint 65 secondary endpoints 64 composite endpoint 64 pharmacodynamic endpoints 64 prospectively defined 63 primary endpoint 63 tanespimycin 63 noninferiority 62 primary efficacy endpoints 62 confirmatory clinical 62 Primary endpoints 62 Secondary endpoints 62 GAMMAGARD 62 primary efficacy endpoint 62 riociguat 62 primary endpoints 61 efficacy tolerability 61 NATRECOR ® 61 Azedra 61 EFAPROXYN 61 MEND CABG II 61 Secondary efficacy endpoints 61 elotuzumab 61 ONCONASE R 61 prespecified 61 UPLYSO 61 Phase IIB 61 RE LY ® 60 ADAGIO study 60 alvimopan 60 pharmacokinetic PK 60 teriflunomide 60 pharmacokinetic equivalence 60 active comparator 60 oral ridaforolimus 60 PRIMO CABG 60 efficacy 60 STRIDE PD 60 phase IIb clinical 60 MoxDuo TM IR 60 PREOS 60 ATACAND 60 CIMZIA ™ 60 antipsychotic efficacy 60 tecarfarin 60 pain palliation 60 pharmacodynamic 59 ADCS CGIC 59 BLA submission 59 endoscopic gastric ulcers 59 ACCORD Lipid 59 ponatinib 59 prognostic indicators 59 Zemplar Capsules 59 MAGE A3 ASCI 59 Dyloject TM 59 cangrelor 59 ruxolitinib 59 placebo controlled clinical 59 CoFactor 59 CIMZIA TM certolizumab pegol 59 tolevamer 59 SYMMETRY trial 59 galiximab 59 Xanafide 59 surrogate markers 59 LEP ETU 59 subgroup analyzes 59 Orazol 59 tocilizumab 59 GSK# [001] 59 achieved statistical significance 59 Prestara 59 dirucotide 59 nonclinical studies 59 haematologic 59 rolofylline 59 INC# 59 INCB# [001] 59 COMFORT II 58 viral kinetics 58 AzaSite Plus 58 CRp 58 Virulizin ® 58 teduglutide 58 nonrandomized 58 nab paclitaxel 58 tolvaptan 58 OvaRex ® MAb 58 Neuradiab 58 varespladib 58 exploratory endpoints 58 phase IIb 58 randomized multicenter Phase III 58 phase IIIb 58 pharmacokinetic PK profile 58 rALLy trial 58 CIMZIA TM 58 Xinlay 58 recurrent GBM 58 cortical stimulation 58 statistical significance 58 systemic immunosuppressive drugs 58 SVR# 58 Pemetrexed 58 bicifadine 58 vismodegib 58 myelofibrosis 58 EDEMA3 trial 58 pertuzumab 58 phase IIa 58 Cloretazine 58 everolimus eluting stents 58 Onrigin TM 58 vidofludimus 58 RE LY 58 MADIT II 58 Hyphanox 58 pharmacodynamic PD 58 KRN# 58 AVADO 58 optimal dosing 58 Cimzia TM 58 oral FTY# 58 virologic response 58 PIX# [002] 58 MEND CABG 58 ACTEMRA TM 58 vemurafenib 58 Ereska 58 Exelixis compounds 58 opioid induced bowel dysfunction 58 endoscopic remission 58 MAP# 58 pharmacodynamic effects 58 analgesic efficacy 58 orBec 58 PNH patients 58 fosbretabulin 58 metabolic parameters 58 PRECISE 58 Prostate AdenoCarcinoma Treatment 58 ASCEND HF 58 morphometric vertebral fractures 58 favorable pharmacokinetic profile 58 MIST II 57 locoregional 57 elagolix 57 Phase IIb clinical 57 BrachySil 57 viral kinetic 57 dosage regimens 57 PEGylated interferon beta 1a 57 Corlux 57 clinically meaningful 57 6R BH4 57 SPIRIT III 57 trastuzumab emtansine T DM1 57 AZILECT R 57 MERLIN TIMI 57 pharmacodynamic properties 57 Vilazodone 57 virological response 57 ACR# [002] 57 registrational 57 Phase IIb III 57 Phase Ib study 57 Dacogen injection 57 refractory Hodgkin lymphoma 57 CARE HF 57 picoplatin 57 Amrubicin 57 bardoxolone 57 CINQUIL 57 FOLPI 57 tolerability pharmacokinetics 57 Octreolin 57 prognostic variables 57 ruboxistaurin 57 multicenter trials 57 cintredekin besudotox 57 Phase IIIb clinical 57 mesalamine granules 57 LymphoStat B 57 relapsing multiple sclerosis 57 ACTEMRA 57 QTc prolongation 57 CCX# 57 diabetic neuropathic pain 57 torezolid phosphate 57 Iloperidone 57 reslizumab 57 NO# [002] 57 comparator arm 57 Phase IIa trials 57 Androxal TM 57 HAMD 57 vandetanib 57 MyVax R 57 Onrigin 57 TELCYTA 57 LHRH antagonists 57 icatibant 57 palliation 57 tipranavir 57 lintuzumab 57 PRECISE trial 57 metastatic HRPC 57 BENICAR HCT 57 placebo controlled trials 57 ADAS cog 57 brivaracetam 57 refractory chronic lymphocytic 57 HCV RESPOND 2 57 MGN# 57 symptomatic VTE 57 Bicifadine 57 interferon gamma 1b 57 Tekamlo 57 ancrod 57 placebo controlled clinical trials 57 Onbrez Breezhaler 57 alvespimycin 57 custirsen 57 cardiovascular morbidity 57 complete cytogenetic response 56 CHAMPION PLATFORM 56 angiographic outcomes 56 Montgomery Asberg Depression 56 tolerability 56 Archexin 56 levosimendan 56 Pirfenidone 56 refractory AML 56 HORIZONS AMI trial 56 Randomized controlled 56 CTAP# Capsules 56 ELND# 56 Phase #b/#a clinical 56 ularitide 56 erlotinib Tarceva ® 56 pharmacodynamic parameters 56 budesonide MMX 56 NATRECOR R 56 IMPROVE HF 56 stratifying patients 56 TAXUS VI 56 achieve statistical significance 56 eTag assays 56 iniparib 56 NV1FGF 56 budesonide foam 56 Ocrelizumab 56 CANCIDAS 56 cediranib 56 AIM HIGH 56 Phase 1a clinical 56 neratinib 56 Q#IR 56 ARB telmisartan 56 Phase Ib clinical 56 OPAXIO 56 QuadraSphere 56 inhibitor RG# 56 novel VDA molecule 56 Edwards SAPIEN valve 56 octreotide implant 56 Panzem R NCD 56 lipid parameters 56 PFO migraine 56 Neuropsychiatric Inventory NPI 56 Xyotax 56 palifosfamide 56 maximally tolerated dose 56 atrasentan 56 limiting toxicity 56 Tolvaptan 56 Campath alemtuzumab 56 placebo controlled Phase III 56 placebo controlled studies 56 REMINYL ® 56 genotypic resistance 56 Phase III clinical 56 PREZISTA r 56 ONTARGET 56 LUMINATE 56 MYDICAR 56 PRE SURGE 56 HRQL 56 SinuNase TM 56 fluoropyrimidine 56 synthetic retinoid 56 YONDELIS 56 R0 resection 56 TAXUS Express Stent 56 Candesartan 56 carotid endarterectomy CEA 56 FOLOTYN ® 56 Doxil ® 56 FDG PET scans 56 EchoCRT 56 ANCHOR trial 56 Phenoptin 56 Entereg TM 56 chemoradiotherapy 56 dimebon 56 PROPEL trial 56 sargramostim 56 pharmacodynamics PD 56 confirmatory Phase III 56 dose limiting toxicities 56 postapproval 56 ADVEXIN therapy 56 preclinical efficacy 56 PITX2 methylation 56 PRIMO CABG2 56 AZD# 56 Zybrestat 56 RoACTEMRA 56 TREDAPTIVE 56 severe gastroparesis 56 ToGA 56 randomized Phase 2b 56 TBC# 56 HuMax EGFr 56 ataluren 56 Trofex 56 CCyR 56 BRAF inhibitor 56 sustained virologic response 56 Pivotal Phase III 56 recurrent glioblastoma multiforme 56 APEX AMI trial 56 SPIRIVA HandiHaler 56 oblimersen 56 multicentre randomized 56 dacarbazine chemotherapy 56 thorough QT 56 apremilast 56 Fodosine 56 Asentar 56 Allovectin 7 ® 56 remission CR 56 RIGScan CR 56 IV NSCLC 56 glufosfamide 55 postoperative ileus 55 mycophenolate mofetil 55 prucalopride 55 phase IIb trial 55 Solid Tumors criteria 55 RECIST Response Evaluation Criteria 55 Azedra TM 55 motavizumab 55 Non inferiority 55 Traficet EN 55 HCV SPRINT 55 PS# [001] 55 ganetespib 55 anti angiogenic agents 55 pharmacodynamic profiles 55 clinico pathological 55 BrachySil TM 55 trastuzumab DM1 55 randomized controlled clinical 55 ARCOXIA 55 non inferiority 55 eculizumab 55 clinical pharmacology studies 55 visilizumab 55 cystinosis patients 55 clinical trial 55 gemcitabine Gemzar ® 55 galantamine 55 TRITON TIMI 55 talactoferrin 55 Panzem R 55 Soliris TM eculizumab 55 VADT 55 pharmacokinetic parameters 55 PEG PAL 55 liposomal doxorubicin 55 cannabinor 55 oral diclofenac 55 dyslipidaemia 55 posaconazole 55 ELACYT 55 pirfenidone 55 clazosentan 55 ELADUR 55 GORE VIABAHN Endoprosthesis 55 sorafenib tablets 55 glatiramer acetate 55 PREOS R 55 edifoligide 55 pharmacokinetic characteristics 55 IL# PE#QQR 55 ECOG 55 vorinostat 55 HGS ETR2 55 LymphoStat B belimumab 55 clinically meaningful improvement 55 TAXUS Liberte Stent 55 KRAS status 55 Hepatocellular Carcinoma HCC 55 Proellex TM 55 therapeutic regimens 55 EURIDIS 55 paliperidone ER 55 OraTest R 55 antiarrhythmic drug 55 F FDG PET 55 Ostarine 55 TLK# 55 sorafenib Nexavar 55 clinically meaningful efficacy 55 ADVEXIN clinical 55 Zenvia ™ 55 Anacetrapib 55 Phase IIa clinical 55 Temsirolimus 55 IIIa inhibitor 55 renal toxicity 55 Genasense R oblimersen 55 FDG PET imaging 55 randomized blinded 55 candesartan cilexetil 55 Phase 2b study 55 BioSTAR R 55 Phase III randomized controlled 55 gefitinib Iressa 55 subanalysis 55 Vidaza ® 55 EOquin 55 Canvaxin 55 Zolinza 55 hemoglobin A1c levels 55 sunitinib malate 55 BRIM3 55 SIMPADICO 55 bosentan 55 sNDA submission 55 Study GL# 55 Vandetanib 55 TKM ApoB 55 statistically significant superiority 55 Zenvia Phase III 55 Pharmacokinetic parameters 55 EMPOWER ™ 55 Thrombolysis 55 Junovan 55 DAPT 55 Degarelix 55 recurrent malignant glioma 55 oxymorphone ER 55 vernakalant hydrochloride 55 Abatacept 55 Zelrix 55 trials RCTs 55 EOquin TM 55 Lenalidomide 55 liver metastases 55 trospium 55 urinary N telopeptide 55 Fibrillex TM 55 multicenter Phase II 55 investigational therapies 55 PXD# 55 Rasilez Tekturna 55 paliperidone palmitate 55 RSD# oral 55 RSR# 55 canakinumab 55 trastuzumab Herceptin 55 ZACTIMA 55 melphalan prednisone 55 desvenlafaxine succinate 55 NP2 Enkephalin 55 Bezielle 55 Phase III HEAT 55 IMPACT IMmunotherapy 55 CYT# QbG# 55 pivotal bioequivalence 55 TNF antagonist 55 Torisel 55 potency selectivity 55 EORTC 55 Alocrest 55 ENRICH trial 55 chronic myocardial ischemia 55 lomitapide 55 AGILECT R 55 NEVO RES 55 APPRAISE 55 prospective multicenter randomized 55 PROMACTA 55 neoadjuvant 55 Tamibarotene 55 Cloretazine R VNP#M 55 Votrient 55 L MTP PE 55 daclizumab 55 Dalbavancin 55 lacosamide 55 MIRCERA 55 calcineurin inhibitors 55 Elagolix 55 SILENOR 55 bevacizumab Avastin ® 55 safinamide 55 catheter occlusion 55 Tasimelteon 55 antidepressant efficacy 55 ROCKET AF 55 Neurodex 55 pediatric acute lymphoblastic 55 Phase IIb clinical trials 55 tumor necrosis 55 ticagrelor 55 faropenem 55 XIENCE V PROMUS Stent 55 OMAPRO 55 multicenter Phase III 55 indiplon capsules 55 StemEx R 55 MGd 55 Microplasmin 55 Bronchitol 55 BENICAR 55 MoxDuo IR 55 Chemophase 55 neoadjuvant treatment 55 elacytarabine 55 Clolar ® 55 DACH platinum 55 CoreValve System 55 Onconase 55 AeroLEF TM 55 erlotinib Tarceva 55 randomized controlled trials RCTs 55 schizophrenia CIAS 55 postoperative chemotherapy 55 sUA 55 methylnaltrexone 55 SCD HeFT 55 alemtuzumab MS 55 Phase III ThermoDox 55 plasma pharmacokinetics 55 relapsed SCLC 55 antiepileptics 55 OvaRex R 55 eprotirome 55 INVEGA ® 55 MDRD equation 55 Golimumab 55 clinically meaningful differences 55 ximelagatran 55 OncoVEX GM CSF 55 chemosensitivity 55 Randomized Evaluation 55 Vidaza azacitidine 55 GLP toxicology studies 54 ARIKACE ™ 54 Phenserine 54 MyVax 54 rosuvastatin #mg 54 tezampanel 54 headache nasopharyngitis 54 regorafenib 54 KIACTA ™ 54 successfully commercialize Iluvien 54 ganaxolone 54 orally inhaled migraine 54 Zerenex 54 Tavocept 54 tolerated dose MTD 54 PROactive study 54 Arikace 54 LIALDA 54 adverse cytogenetics 54 Subgroup analysis 54 ATL# [001] 54 micafungin 54 Safinamide 54 Renal Cell Carcinoma RCC 54 Virulizin R 54 oral rivaroxaban 54 mRCC 54 ADAS Cog 54 clinical trials 54 favorable tolerability 54 GLYX 54 neoadjuvant therapy 54 MICARDIS ® 54 relapsed refractory multiple myeloma 54 Linjeta TM 54 Dapagliflozin 54 alicaforsen enema 54 5-fluorouracil/leucovorin 54 INCB# [003] 54 randomized clinical trials 54 histopathological 54 platelet inhibition 54 BRIM2 54 davunetide intranasal AL 54 investigational antiplatelet agent 54 CBLC# 54 dosing regimens 54 calcineurin inhibitor 54 Complete Response 54 serum phosphorous 54 axitinib 54 antiviral efficacy 54 RE SURGE 54 adjuvant therapies 54 Phase Ib 54 Pyridorin 54 Plenaxis TM 54 satraplatin Phase 54 denufosol 54 rFVIIa 54 otelixizumab 54 dexpramipexole 54 CLIRS trial 54 Phase 2a trial 54 ReN# 54 pharmacokinetic 54 fulvestrant 54 prospective randomized controlled 54 sunitinib 54 low dose cytarabine 54 protease inhibitor PI 54 Fabry Disease 54 everolimus eluting stent 54 intensive lipid lowering 54 NLX P# 54 Meta analyzes 54 lupus renal disease 54 SUCCEED trial 54 ribavirin RBV 54 Cleviprex TM clevidipine 54 metastatic RCC 54 periprocedural MI 54 tiotropium 54 Phase IIa trial 54 MBP# [001] 54 SEPET TM 54 SILENOR TM 54 phase IIa clinical 54 ACUITY trial 54 superficial bladder cancer 54 CYPHER R Sirolimus eluting 54 SILENOR ™ 54 Subgroup analyzes 54 interferon beta therapy 54 phase Ib 54 liprotamase 54 Onalta ™ 54 dasatinib 54 biologic therapy 54 sipuleucel T 54 unresectable malignant mesothelioma UMM 54 progression TTP 54 cytogenetic response 54 tumor histology 54 Azixa 54 macrovascular events 54 guanfacine extended release 54 pharmacokinetic profiles 54 ACZ# 54 lanthanum carbonate 54 TAXUS Stent 54 clinically meaningful improvements 54 INTERCEPT platelets 54 prognostic factors 54 DexaSite 54 proprietary transdermal patch 54 iclaprim 54 Alzheimer Disease Assessment 54 randomized multicenter trial 54 conditional logistic regression 54 TAXUS IV 54 evaluating REVLIMID 54 DU #b 54 FOLFIRINOX 54 demonstrated clinically meaningful 54 AGILECT ® 54 generation purine nucleoside 54 pharmacokinetics PK 54 DAVANAT 54 Rating Scale MADRS 54 doripenem 54 Fibrin Pad 54 K ras mutations 54 #:# randomization 54 substudy 54 CLARITY study 54 pulmonary exacerbations 54 retinal thickness 54 JAK inhibitor 54 dirucotide MBP# 54 DR Cysteamine 54 NYHA Class II 54 Plicera 54 senicapoc 54 Pharmacokinetic PK 54 EDEMA3 54 BAY #-# 54 Neurodex TM 54 DCCR 54 histologies 54 rNAPc2 54 GOUT 54 almorexant 54 eliglustat tartrate 54 BNC# 54 neurologic progression 54 TroVax 54 paclitaxel eluting stents 54 CA9 SCAN 54 midstage clinical trials 54 ARIXTRA 54 IPLEX 54 Pharmacokinetic 54 JAK2 inhibitor 54 pseudobulbar affect PBA 54 dacetuzumab 54 Cellegesic 54 rHuPH# 54 colesevelam HCl 54 PrevOnco 54 Capesaris 54 induced macular edema 54 AVASTIN 54 Secondary endpoints included 54 CA4P 54 SNT MC# 54 ADVANCE PD 54 complete cytogenetic 54 peginesatide 54 FACTIVE tablets 54 OMNARIS HFA 54 Phase IIb trial 54 torsemide ER 54 SYNTAX trial 54 Cloretazine ® 54 clobazam 54 HIV HCV coinfected 54 BCX# 54 Navelbine ® 54 atacicept 54 darapladib 54 Phase 2b clinical 54 NSABP C 54 bevacizumab Avastin 54 bosutinib 54 AZILECT ® 54 olaparib 54 optimal dosing regimen 54 XmAb# 54 active moiety 54 Amigal 54 IRESSA 54 non selective NSAIDs 54 Gefitinib 54 eltrombopag 54 EndoTAG TM -1 54 CRMD# 54 Solazed 54 intravenous methylnaltrexone 54 CAMMS# 54 clevidipine 54 TOLAMBA 54 ALN TTR# 54 fallopian tube cancers 54 CTEPH 54 tolerability profile 54 Dasatinib 54 EmbraceAC 54 phase IIb study 54 AEGR 54 intravenous cyclophosphamide 54 TACI Ig 54 anti leukemic 54 graft dysfunction 54 NEVO ™ 54 endothelin antagonists 54 lucinactant 54 Vidofludimus 54 INCB# [002] 54 MDRD 54 romiplostim 54 chlorambucil 54 Psoriasis Area 54 ENDEAVOR III 54 R# #mg BID 54 HDRS 54 preclinical pharmacokinetic 54 certolizumab 54 Catena ® 54 evaluable subjects 54 Aflibercept 54 NYHA functional class 54 NSABP B 54 prespecified secondary 54 AIR CF2 54 pramlintide metreleptin combination 54 relapsed ALL 53 olanzapine LAI 53 depsipeptide 53 oral prodrug 53 non squamous NSCLC 53 delafloxacin 53 Deforolimus 53 tumor recurrence 53 lumiliximab 53 arzoxifene 53 solanezumab 53 Triapine R 53 immunomodulatory agents 53 ZOLINZA 53 CHAMPION PCI 53 velafermin 53 double blinded placebo 53 SUTENT 53 RELOVAIR ™ 53 lipid lowering agents 53 pediatric malignancies 53 Stedivaze 53 prospective randomized multicenter 53 Events MACE 53 CYP#C# genotype 53 Ranolazine 53 Ceflatonin 53 dose cohort 53 dose proportionality 53 briakinumab 53 DDP# 53 fluvastatin 53 hyperphenylalaninemia HPA due 53 antiangiogenic therapy 53 FDA defined valvulopathy 53 pivotal Phase III 53 ThermoDox ® clinical 53 clinically relevant 53 ZYBRESTAT fosbretabulin 53 QNEXA 53 mTOR inhibitor 53 zalutumumab 53 HoFH 53 Genasense ® oblimersen 53 DermaVir Patch 53 PROVENGE sipuleucel T 53 KNS # 53 secretin 53 obatoclax 53 CYT# potent vascular disrupting 53 O PPDS 53 PRT# 53 tezampanel NGX# 53 PHX# 53 SABCS 53 Index CDAI 53 crizotinib PF # 53 Pivotal Phase 53 Empatic 53 GnRH antagonist 53 assessing T DM1 53 T Pred 53 reboxetine 53 neoadjuvant chemotherapy 53 trastuzumab Herceptin ® 53 dextromethorphan quinidine 53 Augment Injectable 53 PEG IFN 53 Targretin 53 SUTENT ® 53 aclidinium 53 PRECISE Trial 53 FTY# 53 insulin detemir 53 aflibercept 53 rALLy 53 Randomized clinical trials 53 deforolimus 53 YERVOY 53 Phase #b/#a 53 durable pain palliation 53 bortezomib Velcade 53 refractory CLL 53 Dendreon Provenge 53 rALLy clinical trial 53 azacitidine 53 EGFR antibodies 53 response pCR 53 bioequivalence 53 BIBW 53 Phase III trials 53 metastatic castration resistant 53 liver histology 53 OvaRex MAb 53 QTinno 53 Combo Stent 53 Phase Ib clinical trials 53 trial evaluating PRX# 53 farletuzumab 53 β blockers 53 TNF alpha inhibitor 53 Aryplase 53 Combination therapy 53 placebo controlled randomized 53 pharmacokinetics pharmacodynamics 53 OMAPRO ™ 53 adalimumab 53 HuMax CD# 53 ORENCIA ® 53 Prospective Randomized 53 Acetavance 53 TMC# C# 53 follicular NHL 53 MYCAMINE 53 CYT# 53 HAART regimens 53 radiographic outcomes 53 SinuNase 53 CRESTOR #mg 53 FM VP4 53 PEGPH# 53 forodesine 53 irbesartan 53 Tiotropium 53 Tarceva TM 53 PrevOnco ™ 53 APEX PD 53 ILLUMINATE 53 PEG Interferon lambda 53 aetiology 53 Aurexis 53 Telcyta 53 Phase III 53 baminercept 53 trastuzumab DM1 T DM1 53 mg kg BID 53 ExTRACT TIMI 53 IBS C 53 dyskinesia PD LID 53 trabectedin 53 Metastatic Melanoma 53 #mg dose [002] 53 dosing cohorts 53 SEROQUEL 53 sulodexide 53 Ophena TM 53 SPIRIT FIRST 53 carcinogenicity studies 53 invasive aspergillosis 53 Phase IIIb 53 GP IIb IIIa inhibitors 53 phase IIb III 53 kinase inhibition 53 Bortezomib 53 Entereg R 53 pharmacodynamic markers 53 salmeterol fluticasone 53 Taxotere ® 53 metastatic neuroendocrine tumors 53 pharmacokinetic profile 53 Pralatrexate 53 cethromycin 53 Carotid Revascularization Endarterectomy vs. 53 Chrysalin 53 paclitaxel carboplatin 53 refractory gout 53 RCTs 53 Tracleer R 53 VA# [002] 53 Phase IIb 53 nonfatal MI 53 TWYNSTA 53 p# biomarkers 53 Afatinib 53 CLORETAZINE TM VNP#M 53 histone deacetylase HDAC inhibitor 53 Zevalin consolidation 53 GATTEX ™ 53 cardiac toxicity 53 AIR2 Trial 53 VTE prophylaxis 53 Pharmacokinetic studies 53 histologic 53 thalidomide Thalomid 53 enzastaurin 53 RRMS patients 53 BAL# [002]

Back to home page